Special Presentation: DoxyPEP update




TRANSLATING EVIDENCE INTO ACTION FOR PUBLIC HEALTH: THE DOXY-PEP STORY


CDC/HRSA Advisory Committee (CHAC) April 10, 2024

> Stephanie Cohen, MD, MPH Director, HIV/STI Prevention Section SF Department of Public Health



POPULATION HEALTH DIVISION SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH San Francisco has higher chlamydia, gonorrhea, and syphilis rates compared to the United States overall, the state of California, Los Angeles and New York City. 3





In November 2019, US DoxyPEP study launched in San Francisco and Seattle

Why Doxycycline (doxy)?


- Safe, well tolerated, inexpensive oral antibiotic
- Active against chlamydia & syphilis. Approx 80% of gonorrhea strains in US susceptible
- Shown to reduce STIs in two prior studies
 - Small pilot in LA (N=30) of doxy pre-exposure prophylaxis (PrEP)
 - Ipergay study in France (N=232) of doxy post exposure prophylaxis (PEP)
- Strong interest amongst men who have sex with men (MSM)
- US DoxyPEP study, French DOXYVAC and Kenya D-PEP studies aimed to assess the impact of doxy-PEP on bacterial STIs incidence and on drug resistance (in STIs and other bacteria)




DoxyPEP and DOXYVAC studies demonstrated substantial reduction in risk of bacterial STIs in MSM and trans women

Time to first CT, GC or syphilis: DoxyPEP¹

Time to first CT or syphilis: DoxyVAC²



¹DoxyPEP, Luetkemeyer et al, NEJM 2023; 388:1296-1306, ²DOXYVAC, Molina et al, CROI 2024



Kenya D-PEP study *did not* find that doxy-PEP reduced STIs in cis women

- High self-reported adherence (≥80%)
- Median 4 doses per month (IQR 0-8)
- Low hair drug levels in women in doxycycline group suggest low adherence to doxy-PEP

How to implement doxy-PEP in San Francisco?

- Eligibility criteria
- Supporting roll-out and uptake
- Monitoring impacts of doxy-PEP
 - Disparities in uptake
 - STI rates
 - Antimicrobial resistance
 - Adverse events (e.g effect on microbiome)



Who Should be Offered Doxy-PEP?

More restrictive use

- Maximize benefit-risk ratio
- Minimize excess antibiotic use
- More complex to identify candidates
- Reduced reach and impact

<u>Study eligibility</u> MSM or Transwoman *and* Bacterial STI in past year

Broader use

- Meet patient demand
- Anti-stigma
- Greater reduction in absolute number of STIs
- More antibiotics used





SFDPH: First jurisdiction in US to release guidelines for DoxyPEP





Health Update Doxycycline Post-Exposure Prophylaxis Reduces Incidence of Sexually Transmitted Infections

October 21, 2022

Situational Update

Researchers at the San Francisco Department of Health (SFDPH), Zuckerberg San Francisco General, University of California, San Francisco, and the University of Washington recently collaborated on a randomized controlled clinical trial of post-exposure prophylaxis (PEP) of sexually transmitted infections (STIs) using a single dose of doxycycline 200 mg within 72 hours after oral, anal, or vaginal sex, in men who have sex with men (MSM) and transgender women (TGW) who were living with HIV (PLWH) or taking HIV pre-exposure prophylaxis (HIV PrEP). The study showed that this regimen significantly reduced acquisition of chlamydia, gonorrhea, and syphilis in these populations.

Participants randomized to doxycycline PEP (doxy-PEP) had a 66% (HIV-negative and on PrEP) and 62% (PLWH) reduction in STIs per quarter of study follow-up, compared with participants randomized to standard of care (no doxy-PEP). Taking doxycycline was also safe and well-tolerated by participants, with no drug-related serious adverse events. These data were recently presented at the 2022 International AIDS Conference in Montreal, Canada. Data are still being collected and analyzed to assess the impact of doxy-PEP on risk for drug resistance in bacterial STIs, *Staph aureus*, and commensal *Neisseria*, and on the gut microbiome.

The CDC has released <u>considerations</u> for doxy-PEP as an STI prevention strategy, but there is not yet detailed guidance from CDC on doxy-PEP, for which its indication is currently off-label. STIs can cause significant morbidity and reducing STI rates in San Francisco is an urgent public health priority. **Doxy-PEP is the first biomedical prevention tool that has been shown to be effective and well-tolerated, community awareness is growing, and many providers in SF are already prescribing doxy-PEP to their patients at risk for STIs. SFDPH is providing guidance to SF clinicians on the use of doxy-PEP to reduce STI incidence in MSM and TGW at risk of bacterial STIs.**

Doxy-PEP Interim Guidelines





Health Update Doxycycline Post-Exposure Prophylaxis Reduces Incidence of Sexually Transmitted Infections

October 21, 2022

- Recommend doxy-PEP to cis men and trans women who: 1) have had a bacterial STI in the past year and 2) report condomless anal or oral sexual contact with ≥ 1 cis male or trans female partner in the past year. Patients with a history of syphilis should be prioritized for doxy-PEP.
- 2. Offer doxy-PEP using shared decision making to cis men, trans men and trans women who report having multiple cis male or trans female sex partners in the prior year, even if they have not previously been diagnosed with an STI.
- 3. Results from the Kenya D-PEP study found that doxy-PEP was not effective at preventing STIs among cis women. Drug level data suggest that this may have been due to low adherence to doxy-PEP. Providers can consider offering doxy-PEP to cis women on a case-by-case basis, for example to women with a history of syphilis or women who exchange sex for money or drugs.

Readable, concise, non-stigmatizing patient and provider facing education in multiple languages

About Doxy-PEP

What is doxy-PEP?

· Doxy-PEP means taking the antibiotic doxycycline after sex, to prevent getting an STI. It is like a morning-after pill but for STIs. Taking doxy-PEP reduces your chance of acquiring syphilis, gonorrhea, and chlamydia by about two-thirds.

Acerca de Doxy-PEP

El doxy-PEP significa tomar el antibiótico doxiciclina después de las relaciones para prevenir contraer una

· Se toma dos pastillas de doxiciclina de 100 mg dentro de las 24 horas, pero a más tardar 72 horas después

de tener relaciones sexuales sin condón. Las relaciones sin condón significa las relaciones orales, anales o

Si vuelve a tener relaciones dentro de las 24 horas después de tomar doxiciclina, tome otra dosis 24 horas

después de la última dosis. Puede tomar doxicicílina tan frecuentemente como todos los días cuando esté

Evite los productos lácteos, el calcio, los antiácidos o las multivitaminas dentro de las 2 horas antes o 2 horas

· ¿Podría aumentar o disminuir las bacterias que viven en nuestra piel, o hacerlas resistentes a la doxiciclina? · ¿Doxy-PEP aumentará la resistencia a la doxiciclina en las bacterias que causan las ITS?

Aunque la doxiciclina se ha utilizado durante décadas, no parece haber resistencia a la doxiciclina

Airededor del 25% de la gonorrea en los EE, UU, ya es resistente a doxy: doxy-PEP puede no

· Llámenos al 628-217-6692 si se le acaba la doxiciclina, si tiene algún efecto secundario o si cree que puede

El doxy-PEP reduce la posibilidad de contraer sifilis, gonorrea y clamidia, pero estas ITS aún pueden ocurrir.

funcionar contra estas cepas. El estudio DoxyPEP, y otros estudios científicos, nos ayudarán a

reduce la probabilidad de contraer sífilis, gonorrea y clamidia en aproximadamente dos tercios

vaginales/con agujero delantero, en las que no se usa un condón todo el rato.

doxiciclina le produce malestar estomacal, puede ser útil tomarla con alimentos. Algunas personas son más sensibles al sol cuando toman doxiciclina, así que use protector solar.

después de tomar doxiciclina para una absorción óptima de doxiciclina en el cuerpo.

comprender si el uso de doxy-PEP cambia la resistencia en la gonorrea.

Continúe haciéndose la prueba a intervalos regulares y si tiene síntomas.

Doxy-PEP no protege contra MPX (viruela del mono). VIH u otras infecciones virale

¿Qué estamos aprendiendo todavía sobre doxy-PEP?

¿Afecta las bacterias normales ("buenas") en nuestros intestinos

infección de transmisión sexual (ITS). Es como una pastilla del día después pero para las ITS. Tomar doxy-PEP

¿Qué es doxy-PEP?

¿Cuándo debo tomar doxy-PEP?

¿Cómo debo tomar doxy-PEP?

SPF 157

Q

\$ D

Recordatorios

tener una ITS.

¿Y qué pasa si vuelvo a tener relaciones?

No comparta la doxiciclina con otras personas.

en la clamidia ni en la sífilis

When should I take doxy-PEP?

 Two 100 mg pills of doxycycline should be tak after condomless sex. Condomless sex means isn't used for the entire time. What about when I have sex again?

 If you have sex again within 24 hours of takin last dose. You can take doxycycline as often a don't take more than 200 mg (two 100 mg pil

How should I take doxy-PEP?

 Take doxycycline with plenty of water or som you swallow. If your stomach is upset by doxy Some people are more sensitive to the sun w SPF 15 · Please do not share doxycycline with others. · Avoid dairy products, calcium, antacids, or m

What are we still learning about doxy-

· Does it affect normal ("good") bacteria in our Could it increase or decrease the bacteria that doxycycline (for example staph)? Will doxy-PEP increase doxycycline resistance Although doxycycline has been used for de chlamydia or syphilis About 25% of gonorrhea in the US is alrea these strains. The DoxyPEP study and othe

PEP changes resistance in gonorrhea.

Reminders

<u>೨</u>

Ð

Call us at 628-217-6692 if you run out of doxy think you may have an STI. Please continue to get tested for STIs every 3

Doxy-PEP doesn't protect against MPX (monk





Doxy-PEP fact sheet for healthcare providers in San Francisco

What is doxy-PEP?

Doxycycline post-exposure prophylaxis (doxy-PEP) is using doxycycline 200 mg within 72 hours after oral, anal, or vaginal sex to prevent the acquisition of chlamydia, gonorrhea, and syphilis.

A recent study showed daxy-PEP was effective among men who have sex with men (MSM) and trans women living with HIV (62% reduction in acquisition) or taking HIV PrEP (65% reduction).¹ Efficacy against other bacterial sexually transmitted infections (STIs) is not known, and doxy-PEP does not prevent HIV, monkeypox (mpox), or other viral infections.

Who can take doxy-PEP?

Recommend doxy-PEP to gay, bisexual, and other MSM and trans women who:

 have had condomless sex with ≥ 1 cis man or trans woman in the past year, and have had an STI in the past year.

Offer doxy-PEP using shared decision-making to cis men, trans women, trans men, and other gender diverse patients who:

 have had condomless sex in the past year with ≥ 2 cis men or trans women regardless of STI history.

More data is needed on the efficacy of doxy-PEP in cis women.

The only study to date among cis women did not find doxy-PEP effective at preventing STIs, possibly due to adherence.² If prescribing doxy-PEP to cis women due to STI risk factors like multiple STIs or sex work, discuss lack of efficacy data and advise not to use when pregnant.

Dosing and prescribing guidance

 200 mg of doxycycline taken as soon as possible after condomless oral or anal sex, but no later than 72 hours afterward.

· Doxycycline can be taken every day depending on frequency of sexual activity, but no more than 200 mg within a 24-hour period.

Acceptable formulations:

- Doxycycline hyclate or monohydrate immediate release 100 mg (2 tabs taken together)
- Doxycycline hyclate delayed release 200 mg (1 tab), but typically much costlier
- Example Rx: doxycycline 100 mg, #60, 1 refill, take 2 capsules (200 mg) by mouth as needed ASAP after condomless sex, and no later than 72 hours after. Do not take more than 200 mg in a 24-hour period.
- ICD-10 diagnosis code Z20.2 (Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission).

althcare providers in San Francisco

buld I monitor patients taking doxy-PEP?

nonths, screen for gonorrhea and chlamydia at all anatomic sites of exposure, and HIV (if not known to be living with HIV).

nt is diagnosed with an STI while using doxy-PEP, they should be treated to standard CDC STI treatment guidelines (www.bit.ly/STI_guides).

nt utilizing doxy-PEP reports:

ure to a sexual partner with syphilis: epi-treat for syphilis per standard of care. ure to a sexual partner with gonorrhea or chlamydia: consider waiting on atment until test results are back using shared decision-making with patient.

ould I counsel patients taking doxy-PEP?

ycycline with fluids and remain upright for 30 minutes after the dose to reduce hagitis. Taking doxycycline with food may increase tolerability.

gainst sun sensitivity. Patients should be counseled to wear sunscreen and/or longed sun exposure while taking doxycycline.

xycycline during pregnancy. Patients who could get pregnant should receive y testing and be counseled to stop doxycycline if they become pregnant.

a rare risk of benign intracranial hypertension and other serious side effects.

nown risks of doxy-PEP related to the microbiome and antibiotic resistance.

ailed information in our patient-facing counseling handout and dosing instructions.

mprehensive sexual health services

/ PrEP to all sexually active people if they are not already taking it. Options include P, 2-1-1 PrEP, and injectable PrEP.

eople living with HIV are in care and inform patients that maintaining an able HIV viral load eliminates the risk of transmitting HIV to sexual partners,

nonths, screen for gonorrhea and chlamydia (using urine, pharyngeal, and rectal sting) and syphilis, regardless of HIV serostatus.

ions should be offered for eligible individuals. These could include mpox), meningococcal (MenACWY), hepatitis A, hepatitis B, and HPV.

iled guidance, visit our website (sfcityclinic.org): www.bit.ly/doxy-PEPupdate or contact Alyson Decker: alyson.decker@sfdph.org

F, et al. Postexposure Doxycycline to Provent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023; 388 1296-1306 Desverting Prophylaxis to Prevent Security Transmitted Infections in Women, N Engl J Med. 2023; 389(25):2331-2340.










Doxy-PEP as part of a comprehensive package of sexual health services



SF City Clinic began offering doxy-PEP in November 2022

- SF City Clinic (SFCC) is a nationally-recognized center of excellence in sexual health services
- Offers integrated HIV, STI and reproductive health care grounded in a syndemic approach
- Drop-in and appointments available
- High Volume: 17,000 visits annually
- Serve a diverse population
 - 39% B/AA or Latino, 15% Asian
 - 40% <30 years
 - 50% LGBTQ






High uptake of doxy-PEP at SFCC

- At SF City Clinic, MSM and TGW are systematically informed about doxy-PEP at PrEP initiation or PrEP follow-up
- Between November 2022 and May 2023:
 - 74% of patients with GC, CT or syphilis in prior year started doxy-PEP
 - 60% of patients with ≥ 2 sex partners, but no STI history started doxy-PEP
 - Uptake was associated with having a higher # of sex partners in prior 3 months; not with demographic factors




High uptake of doxy-PEP in San Francisco after release of guidelines



- Sentinel surveillance at 1 safety-net HIV clinic and 2 sexual health clinics
- High volume health maintenance organization and primary care clinics not included

Doxy-PEP Uptake by Race/Ethnicity at 2 Sexual Health Clinics (SHC) and 1 HIV Care Clinic San Francisco, Oct 2022 – Dec 2023



Patient Experience and Adverse Events

- Patients report using doxy-PEP selectively
 - At follow-up visits, 89% of those prescribed doxy-PEP reported using it, but not with every condomless sex act
- Occasional discontinuations related to GI side effects
- Sex-positive and person-first intervention
 - Improved peace of mind and sexual pleasure
 - Decreased stigma around STI diagnosis and disclosure
 - Increased self-awareness about sexual behavior
 - Facilitates communication with partners about sexual health

Emotionally...that confidence [due to doxy-PEP] counts for a lot in terms of my mood, and my positivity, and my... sex positivity...before, there would be this kind of cloud of shame come over [a sex act]. (Age 44, HIV-, Seattle)


Decline in chlamydia and syphilis among PrEP patients receiving doxy-PEP at sexual health clinics in SF

	CBO-run sexual health clinic 6/1/22-9/1/23	Municipal sexual health clinic 11/3/21-10/30/23
Chlamydia	67% decrease [IRR: 0.33, 95% CI: 0.23-0.46]	90% decrease [RR: 0.10, 95% CI: 0.05-0.21]
Syphilis	78% decrease [IRR 0.22, 95% CI: 0.09-0.54]	56% decrease [RR 0.44, 95% CI 0.21-0.92]
Gonorrhea	11% decrease [IRR 0.89, 95% CI 0.69-1.15]	23% decrease [RR 0.77, 95% CI 0.58–1.02]




Scott H, CROI 2024 (abstract #126); Bacon O, CROI 2024 (poster #1151)

Decline in **citywide** chlamydia and early syphilis cases in MSM in SF after release of doxy-PEP guidelines



Sankaran M, CROI 2024 (abstract #127)

No decline in **citywide** gonorrhea cases in MSM, and continued increases in chlamydia in cis women in SF after release of doxy-PEP guidelines



---- Pre-period trend ---- Predicted trend ---- Post-period trend

Conclusions

- SFDPH moved quickly to translate evidence from a research study into services for our community
- Remarkable citywide collaboration and our engaged community facilitated early adoption of this new tool
- Early evidence of a population-level impact of doxy-PEP on chlamydia and syphilis rates, but not gonorrhea
 - Longer follow-up and to replicate findings in other jurisdictions
 - Information about antimicrobial resistance
- Providers should support their patients in assessing their need for, interest in, and use of doxy-PEP
- Guidelines for doxy-PEP can and should evolve as evidence emerges, informed by community input



THANK YOU!

SF City Clinic Patients & Study Participants



LINCS

People.Care.Prevention



POPULATION HEALTH DIVISION SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

> ZUCKERBERG SAN FRANCISCO GENERAL Hospital and Trauma Center






Maddie Sankaran Dave Glidden Oliver Bacon Trang Nguyen Bob Kohn Franco Chevalier Judith Sansone Montica Levy Christopher Ruiz Alyson Decker Julia Janssen Erin Antunez Rebecca Shaw Meya Harris Jennifer Lopez Jasmine Hawkins Frank Strona Ricardo Beato Romeo de la Roca Thu Tran Gina Limon Shornora Miller Yong Chun Huang Shai Wallace **Terry Marcotte Bettemie Prins** Clara Shayevich Edward Liu **Flizabeth Faber** Sally Grant

Tony Sayegh Tae-Wol Stanley **Yvonne Piper** Sari Bushman Ameera Snell Tamar Besson Nyisha Underwood Thomas Knoble Hanna Hjord Oscar Macias Nikole Trainor **Rio Bauce** Frank Strona Ricardo Beato Alejandro Vigil Grecia Sambrano Meyana Tillman Francisco Garcia Johnson Mao Tova Israel Wendy Ho Antonia Guatemala Jonathan Carlson Amy Kwan Rho* Torres Anthony Taylor **Crecy James** Pearl Aine Wanda Anderson Veronica Aburto

Adrian Vargas Joey Sweazey **Ki-Shawna Hampton Ryanne Brown** Rigoberto Mendez Alison Cohee Melody Nasser Dorien Cimmiyotti Nikolas Alves da Costa E Silva Annie Luetkemever Connie Celum Susan Buchbinder Chase Cannon Julie Dombrowski Hyman Scott Jorge Roman Jason Bena Matt Spinelli Thiago Torres Courtney Liebi Brad Hare Jonathan Volk SF Getting to Zero DoxyPEP study team Susan Philip Grant Colfax

Surveillance systems to monitor for anti-microbial resistance

Neisseria gonorrhoeae — Prevalence of Tetracycline, Penicillin, or Ciprofloxacin Resistance* or Elevated Cefixime, Ceftriaxone, or Azithromycin Minimum Inhibitory Concentrations (MICs)†, by Year — Gonococcal Isolate Surveillance Project (GISP), 2000–2022



https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fst atistics%2F2022%2Fslides%2F2022-STI-Surveillance-All-Slides.pptx&wdOrigin=BROWSELINK

- CDC supports sentinel surveillance for culture-based GC antibiotic susceptibility testing
- Need systems for monitoring non-STI pathogens, including staph aureus, strep pneumo and E. coli
- Challenging to discern specific impacts of doxy-PEP in context of overall doxycycline use in medicine and agriculture

THE FENWAY INSTITUTE



DoxyPEP at a Boston Community Health Center and National Survey Data

Kenneth H. Mayer, MD CDC-HRSA HIV/AIDS Advisory Committee

April 10th, 2024

thefenwayinstitute.org



Based in downtown Boston, Massachusetts Federally Qualified Healthcare Center, Founded 1971

Mission To enhance the wellbeing of the LGBTQIA+ community as well as people in our neighborhoods and beyond through access to the highest quality health care, education, research, and advocacy

Serving \approx 35,000 patients, with approximately 2,200 PLHIV and 3,500 on PrEP.

ENWA

THE FENWAY

INSTITUT

The Fenway Institute

- Research, Education, Policy
- Involved in NIH and other funded HIV Prevention Research



Guidelines in the US

Local / state health departments

• First to put out recommendations after the large trials were announced



SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

POPULATION HEAL

Recommendations

- Recommend doxy-PEP to cis men and trans women who: 1) have had a bacterial STI in the past year and 2) report condomless anal or oral sexual contact with ≥ 1 cis male or trans female partner in the past year. These were the eligibility criteria used for the DoxyPEP study. Patients with a history of syphilis should be prioritized for doxy-PEP.
- 2. **Offer doxy-PEP using shared decision making** to cis men, trans men and trans women who report having multiple cis male or trans female sex partners in the prior year, even if they have not previously been diagnosed with an STI.

NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE

✓ ALL RECOMMENDATIONS: DOXYCYCLINE POST-EXPOSURE PROPHYLAXIS TO PREVENT BACTERIAL SEXUALLY TRANSMITTED INFECTIONS

Biomedical Prevention of STIs


- Clinicians should offer doxy-PEP to cisgender men and transgender women who are taking HIV PrEP or receiving HIV care and 1) engage in condomless sex with partner(s) assigned male sex at birth and 2) have had a bacterial STI diagnosed within the past year and are at ongoing risk of STI exposure. (A1)
- Clinicians should offer doxy-PEP to cisgender men and transgender women who are *not* taking HIV PrEP or receiving HIV care and 1) engage in condomless sex with partner(s) assigned male sex at birth and 2) have had a bacterial STI diagnosed within the past year and are at ongoing risk of STI exposure. (A2[†])
- Clinicians should engage in shared decision-making with cisgender men who 1) engage in condomless sex with multiple partners assigned female sex at birth and 2) have had a bacterial STI diagnosed within the past year, offering doxy-PEP on a case-by-case basis. (B3)
- When prescribing doxy-PEP, clinicians should use the dosing regimen of oral doxycycline 200 mg taken ideally within 24 to 72 hours of condomless sex (A1) and counsel patients (A*) on the key points for patient education outlined in <u>Table 1: Considerations</u> for <u>Doxy-PEP Implementation</u>.
- For individuals taking doxy-PEP, clinicians should screen for HIV, chlamydia, gonorrhea, and syphilis at least every 3 months. (A1)
- Clinicians should offer HIV PrEP to individuals who do not have HIV and are initiating or using doxy-PEP. (A*)
- Clinicians should <u>offer HIV treatment</u> to individuals with HIV who are not on antiretroviral therapy and are initiating or using doxy-PEP. (A1)

burnet.edu.au

 $\label{eq:stable} \textbf{Abbreviations:} doxy-PEP, doxycycline post-exposure prophylaxis; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.$



"Focused" Identification Of Doxy-PEP Candidates



Traeger MW, CID 2023


Efficiency = $\frac{\% \text{ of STIs prevented}}{\% \text{ of individuals prescribed}}$



□ Assign Male At Birth, ≥18yo

- Plus one of the following -
 - □ A diagnosis of a bacterial STI in the last 12 months
 - \Box PrEP Use, \geq 2 sexual partners with condomless oral/anal sex
 - \Box PLWH, \geq 2 sexual partners with condomless oral/anal sex

□ Shared Decision Making



THE FENWAY INSTITUTE

Doxycycline 100mg take two tabs by mouth within 72 hours after condomless sexual activity (#50, RF1)

What is it for?

To help prevent getting chlamydia, syphilis and gonorrhea. It is not 100% protective but early data suggests it can decrease numbers by 60%!

How do I take it? "3-2-1"

- 3 within 3 days or 72 hours
- 2 take 2 tabs (or 200mg)
- 1 once (limit to 1 time in one day)

- Take Doxycyline 100mg x 2 tabs (200mg together) once within 72 hours of possible exposure / risk - such as <u>condomless</u> oral/anal sex. It is better to take it within the first 24 hours.

- Do not take more than 200mg in one day. It is safe to take daily.
- Take with 8 oz of water and food if possible to help decrease any side-effects

Other important things to consider:

- We are <u>still learning</u> about the effects of <u>DoxyPEP</u> on "good" bacteria of the gut, changes to the bacteria that live on our skin (for example staph), and possible changes in resistance to <u>STIs</u> such as gonorrhea.
- Although doxycyline has been used for decades, there has been <u>no resistance to</u> <u>doxycyline in chlamydia or syphilis.</u>
- If you are having symptoms of an STI, come in to get tested and treated otherwise continue your routine testing every 3 months.
- Doxycycline is not advised for persons that are pregnant/breastfeeding.

We may reach out to you through <u>MyChart</u> at some point in the next few months to see how your experience with <u>DoxyPEP</u> has been going. This helps us to learn, make changes, and help others.














THE FENWAY INSTITUTE


thefenwa_____titute.org





Black or African American White Asian Other

Hispanic, Latinx – 15.6% PrEP user (at end of follow-up) - 73.9% Living with HIV (at end of follow-up) - 8.8%



- By the end of 2023, 1712 pts received doxyPEP prescriptions
- STI testing frequency increased, while percent positive tests for syphilis and CT were decreased, c/w clinic level impact



Comparison of DoxyPEP users with other men screened for a bacterial STI (bSTI) at Fenway Health (N=4,927; >1100 doxyPEP users, Fall 2023)

Variable	DoxyPEP Users	DoxyPEP Non-Users		95% C.I.
PrEP Users	73.8%	39.9%	4.25	3.67-4.93
Private	85.4%	71.3%	2.37	1.96-2.81
Insurance				
bSTI dx in 2022	31.3%	15.0%	1.67	1.42-1.98
PLHIV	8.6%	18.1%	0.42	0.34-0.53

DoxyPEP uptake: •24.1% of patients with an active PrEP prescription •4.8% of PLHIV •13.7% of those screened for a bSTI in 2022 •24.7% of those diagnosed with a **bSTI** in 2022

National Survey of Antibiotic Prophylaxis (Trager et al, CROI 2024)

903 respondents recruited on MSM sex networking sites, Sept 2023 WA ΜТ ND OR MN ID SD WY IA NE NV OF UT СО CA KS MO NC TN OK ΑZ SC NM AR GA >50 11-30 6-10 1-5 HI 🏠 o 🔾 \$0 and.

Demographics


Mean age = 42 years

866 (96%) were assigned male sex at birth Of which 96% identified as gay or bisexual male

> 19% living with HIV 42% using HIV PrEP



US Survey Of MSM STI Antibiotic Prophylaxis (Traeger Et Al) 903 MSM Recruited Via Sex Networking Apps



Preliminary results (Traeger et al)

45% had used antibiotics before sex

72% had used it after sex

With casual sex partner in the past 12m:


47% used it some of the time

32% used is most of the time


21% used it all of the time

For DoxyPEP users

24% had used a dosage other than a single 200mg dose (recommended)



When using antibiotics around the time of sex to prevent getting an STI, which antibiotics have you used?



Where did you get the antibiotics?



Conclusions

- DoxyPEP scale up was feasible and highly acceptable at a Boston community health center
- Attention to ensuring equity remains important
- Early suggestions that doxyPEP roll-out may be having a local population impact need further study
- National data suggest high levels of interest and some possible misuse of antibiotic prophylaxis
- Community and provider education and clear guidelines are important in order to enhance optimal uptake.

FENWAY INSTITUTE FENWAY EII HEALTH



Thank You

Taimur Khan, Doug Krakower, Jess Kraft, Julia Marcus, Sy Gitin, Michael Traeger NCSD, NACCHO and CDC (Rebekah Horowitz, Lucy Slater, Lindley Barbee)

